Four pre-exposure prophylaxis (PrEP) users with gastro-intestinal disorders (sleeve gastrectomy, terminal ileitis, celiac disease or chronic diarrhea) and receiving oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) were included. Despite a self-reported high adherence, trough plasma tenofovir concentrations (after a supervised intake) were significantly lower than those observed in PrEP recipients without gastrointestinal disorders [21 (±9.1) vs. 138 (±85) ng/mL]. PrEP users with gastrointestinal disorders may need increased TDF doses or alternative prophylactic measures.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7927807 | PMC |
| http://dx.doi.org/10.1128/AAC.01902-20 | DOI Listing |
Publication Analysis
Top Keywords
gastrointestinal disorders
12
pre-exposure prophylaxis
8
recipients gastrointestinal
8
prep users
8
low tenofovir
4
tenofovir plasma
4
plasma exposure
4
exposure hiv
4
hiv oral
4
oral pre-exposure
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!